Robert Lanza is Chief Scientific Officer at ADVANCED CELL TECHNOLOGY, INC. (ACTC). They have made 13 open-market trades across 2 companies since 2010, most recently 2016-02-10.
CIK 0001317093
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OCAT | SELL · 10b5-1 | 2015-11-10 | 2015-11-10 | $8.29 | $207K | N/A | N/A | N/A |
| ACTC | SELL · 10b5-1 | 2014-07-03 | 2014-07-07 | $0.08 | $120K | N/A | N/A | N/A |
| ACTC | SELL | 2012-12-14 | 2012-12-18 | $0.06 | $80K | N/A | N/A | N/A |
| ACTC | SELL | 2012-07-30 | 2012-08-01 | $0.08 | $160K | N/A | N/A | N/A |
| ACTC | SELL | 2012-01-23 | 2012-01-25 | $0.19 | $1.4M | N/A | N/A | N/A |
| ACTC | SELL | 2011-09-28 | 2011-09-30 | $0.15 | $109K | N/A | N/A | N/A |
| ACTC | SELL | 2010-12-06 | 2010-12-08 | $0.14 | $275K | N/A | N/A | N/A |
| ACTC | SELL | 2010-11-29 | 2010-12-01 | $0.10 | $460K | N/A | N/A | N/A |
| ACTC | SELL | 2010-11-22 | 2010-11-24 | $0.07 | $106K | N/A | N/A | N/A |
| ACTC | SELL | 2010-09-20 | 2010-09-22 | $0.07 | $42K | N/A | N/A | N/A |
| ACTC | SELL | 2010-08-20 | 2010-08-23 | $0.08 | $48K | N/A | N/A | N/A |
| ACTC | SELL | 2010-07-20 | 2010-07-23 | $0.07 | $42K | N/A | N/A | N/A |
| ACTC | SELL | 2010-06-21 | 2010-06-23 | $0.10 | $60K | N/A | N/A | N/A |
| ACTC | SELL | 2010-05-20 | 2010-05-21 | $0.07 | $42K | N/A | N/A | N/A |
| OTCBB | SELL | 2010-04-20 | 2010-04-23 | $0.09 | $40K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.